(Q34289726)

1 August 2017

1 reference

title

The hidden impact of antibacterial resistance in respiratory tract infection. Clinical failures: the tip of the iceberg? (English)

1 reference

1 August 2017

Garau J

1

1 reference

1 August 2017

publication date

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

95 Suppl A

1 reference

1 August 2017

page(s)

S5-11; discussion S26-7

1 reference

The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Antibiotic susceptibility patterns of Streptococcus pneumoniae in china and comparison of MICs by agar dilution and E-test methods

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Measuring the comparative efficacy of antibacterial agents for acute otitis media: The “Pollyanna phenomenon”

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

The antibiotic treatment of acute otitis media and sinusitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Penicillin-resistant pneumococci and community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Overwhelming pneumococcal pneumonia in a patient receiving ofloxacin for antimicrobial prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Infectious Complications with Respiratory Pathogens despite Ciprofloxacin Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Clinical use of the quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Pharmacokinetics of ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

Emergence in france of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2801%2990022-8

7 January 2021

10.1016/S0954-6111(01)90022-8

Identifiers

DOI

1 reference

1 August 2017

1 reference